Leading pharma services network brings unmatched scalability, flexibility and expertise to support the global response

Agreement aims to expedite local biomarker testing of NSCLC patients eligible for entrectinib in Japan

Next-Generation Sequencing solutions of Thermo Fisher Scientific help identify IDH1 and IDH2 Mutations in Low-Grade Glioma Patients

Agreement centers on identifying HER2 gene mutations using Oncomine Dx Target Test

Reliable, easy-to-use cryo-EM workflow solution quadruples throughput for pharma labs